Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More

Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
A large-scale study analyzing the genetic data of 23andMe customers has identified specific variants in two genes that significantly influence…
Read More
On May 12, 2025, a significant executive order signed by then-US President Donald Trump mandated the US Department of Health…
Read More